Covid-19: World’s first human challenge trials to start in UK

Epigraph:

Every human life is precious and sacred and saving one is like the saving of the whole of humanity. (Al Quran 5:32/33)

Source: BBC

Healthy, young volunteers will be infected with coronavirus to test vaccines and treatments in the world’s first Covid-19 “human challenge” study, which will take place in the UK.

The study, which has received ethics approval, will start in the next few weeks and recruit 90 people aged 18-30.

They will be exposed to the virus in a safe and controlled environment while medics monitor their health.

The UK has given doses of a Covid vaccine to more than 15 million people.

Human challenge studies have played a vital role in pushing the development of treatments for a number of diseases, including malaria, typhoid, cholera and flu.

The trials will help scientists work out the smallest amount of coronavirus needed to cause infection, and how the body’s immune system reacts to it.

This will give doctors a better understanding of Covid-19, the disease caused by the virus, which will feed into the development of vaccines and treatments.

‘Unique insights’

The Human Challenge study is being delivered by a partnership between the UK government’s Vaccines Taskforce, Imperial College London, the Royal Free London NHS Foundation Trust and the company hVIVO, which has pioneered viral human challenge models.

Read further

Categories: Vaccine

1 reply

  1. The Science Behind Why New Covid Variants Are Spreading Faster
    As highly transmissible coronavirus variants sweep across the world, scientists are racing to understand why these new versions of the virus are spreading faster, and what this could mean for vaccine efforts. New research says the key may be the spike protein, which gives the coronavirus its unmistakable shape. Illustration: Nick Collingwood/WSJ

    https://www.wsj.com/video/the-science-behind-why-new-covid-variants-are-spreading-faster/5E33020B-2FA6-4607-99B8-95CFE1068E06.html?mod=hp_lead_pos13

Leave a Reply